SEC filings and other documents

Lead gene editing program targets Hemophilia A with durable efficacy and IND submission set for Q4.

IND submission for MGX-001 in hemophilia A on track, with strong cash runway into 2027.

Directors and auditor were approved, with no stockholder questions or new nominations.

MGX-001 gene-editing therapy targets curative hemophilia A with IND in Q4 and rapid clinical readouts.

MGX-001 advances toward IND filing in Q4 2026, supported by robust cash and pipeline progress.

MGX-001 advances toward clinical trials as a durable, one-time gene-editing cure for hemophilia A.

Advanced genome-editing pipeline and maintained strong cash position, despite a wider net loss.

Lead hemophilia A program shows curative potential; pipeline and partnerships drive 2025–2027 milestones.

MGX-001 advances, pipeline prioritized, and cost cuts extend cash runway into 4Q 2027.

Q2 2025 net loss widened to $19.9M, with $205M cash supporting operations into 2027.

AI-powered genome editing platform advances curative therapies for genetic diseases.

Durable hemophilia A data, strong cash runway, and platform advances mark Q1 2025.

Durable gene editing for hemophilia A advances toward IND, with strong platform and partnerships.

Gene-editing platform advances and strong preclinical data drive 2026 clinical plans.

Advanced hemophilia A program and maintained strong cash position for operations into 2027.

Advanced hemophilia A program and strong cash position support pipeline and collaborations.

Gene-editing platform shows durable results in hemophilia A and advances broad pipeline, partnerships.

Durable gene editing advances and strategic partnerships drive clinical progress toward 2026 IND.

Durable gene editing in Hem A and rapid pipeline progress highlight platform strength.

Gene editing therapy achieved year-long, stable Factor VIII expression in primates, supporting curative potential.

Q2 2024 revenue up, net loss narrowed, $299.9M cash on hand, funding expected into 2027.